Document Type : Original Research

Authors

1 Department of Pathology, Zagazig University Faculty of Medicine, Zagazig, Egypt

2 Pathology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt

3 Faculty of Medicine, Zagazig University, Zagazig, Egypt

4 Department of Pathology, Faculty of Medicine, University of Benghazi, Benghazi, Libya

5 Department of Pathology, Faculty of Medicine, University of Benghazi, Benghazi, Benghazi Libya

6 Department of Basic Medical Sciences, Unaizah College of Medicine and Medical Sciences, Qassim University, Unaizah, Kingdom of Saudi Arabia. of Benghazi, Benghazi, Libya

7 Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt

8 Department of General Surgery, Faculty of Medicine, Zagazig University, Zagazig, Egypt

9 Department of General Surgery, Faculty of Medicine, Zagazig University Zagazig, Egypt

Abstract

Background & Objective: Cells of renal cell carcinoma (RCC) are resistant to the most currently used chemotherapeutic agents and targeted therapies; hence, we evaluated the expression of NEK2, JMJD4, and REST in tissues of clear cell renal cell carcinoma (ccRCC) and benign nearby tissues of kidney with the aim of detecting associations between their expression and clinicopathological features, prognostic data, tumor recurrence, and survival rates.
Methods: We collected 200 samples from tumor and adjacent non-neoplastic tissues of 100 ccRCC patients. All samples were evaluated for the expression of NEK2, JMJD4, and REST, and the patients were followed up for about 5 years. Tumor recurrence and survival data were collected and analyzed.
Results: NEK2 and JMJD4 expression was increased in ccRCC tissues (P=0.002 and 0.006), while REST was downregulated (P<0.001). The elevated expression of NEK2 was positively related with big tumor size (P=0.015), higher grades (P=0.002), higher stages (P=0.013), distant spread (P=0.004), tumor recurrence, shorter progression-free survival (PFS) rate, and overall survival (OS) rate (P<0.001). Likewise, the high expression of JMJD4 was positively related with big tumor size (P=0.047), higher grades (P=0.003), higher stages (P=0.043), distant spread (P=0.001), tumor recurrence, shorter PFS rate, and OS rate (P<0.001). Conversely, Low expression of REST was positively related to big tumor size, higher grades, higher stages, distant spread, tumor recurrence, and shorter PFS and OS rates (P<0.001).
Conclusion: We demonstrated that overexpression of NEK2 and JMJD4 and downregulation of REST were found in malignant than benign renal tissues and were related to unfavorable pathological findings, poor clinical parameters, and poor patient outcomes.

Keywords

Main Subjects

  1. Luo J, Luo X, Liu X, Fang Z, Xu J, Li L. DUSP9 suppresses proliferation and migration of clear cell renal cell carcinoma via the mTOR pathway. OncoTargets Ther. 2020;13:1321. [DOI:10.2147/OTT.S239407] [PMID] [PMCID]
  2. Wang J, Tang C, Yang C, Zheng Q, Hou Y. Tropomyosin-1 functions as a tumor suppressor with respect to cell proliferation, angiogenesis and metastasis in renal cell carcinoma. J Cancer. 2019;10(10):2220. [DOI:10.7150/jca.28261] [PMID] [PMCID]
  3. Yan H, Bao Y, Lin Z. High Expression of JMJD4 Is a Potential Diagnostic and Prognostic Marker of Renal Cell Carcinoma. Dis Markers. 2021;2021. [DOI:10.1155/2021/9573540] [PMID] [PMCID]
  4. Clark EA, Draves KE. Activation of macaque T cells and B cells with agonistic monoclonal antibodies. Eur J Immunol. 1987;17(12):1799-805. [DOI:10.1002/eji.1830171219] [PMID]
  5. Fang Y, Zhang X. Targeting NEK2 as a promising therapeutic approach for cancer treatment. Cell Cycle. 2016;15(7):895-907. [DOI:10.1080/15384101.2016.1152430] [PMID] [PMCID]
  6. Wang C, Huang Y, Ma X, Wang B, Zhang X. Overexpression of NEK2 is correlated with poor prognosis in human clear cell renal cell carcinoma. Int J Immunopathol Pharmacol. 2021;35:20587384211065893. [DOI:10.1177/20587384211065893] [PMID] [PMCID]
  7. Alam R, Abdolmaleky HM, Zhou JR. Microbiome, inflammation, epigenetic alterations, and mental diseases. Am J Med Genet B Neuropsychiatr Genet. 2017;174(6):651-60. [DOI:10.1002/ajmg.b.32567] [PMID] [PMCID]
  8. Zhang J, Jing L, Li M, He L, Guo Z. Regulation of histone arginine methylation/demethylation by methylase and demethylase. Mol Med Rep. 2019;19(5):3963-71. [DOI:10.3892/mmr.2019.10111] [PMID] [PMCID]
  9. Nakano Y, Kelly MC, Rehman AU, Boger ET, Morell RJ, Kelley MW, et al. Defects in the alternative splicing-dependent regulation of REST cause deafness. Cell. 2018;174(3):536-48. e21. [DOI:10.1016/j.cell.2018.06.004] [PMID] [PMCID]
  10. Alshawli AS, Wurdak H, Wood IC, Ladbury JE. Histone deacetylase inhibitors induce medulloblastoma cell death independent of HDACs recruited in REST repression complexes. Mol Genet Genomic Med. 2020;8(10):e1429. [DOI:10.1002/mgg3.1429] [PMID] [PMCID]
  11. Lv C, Li Y, Zhang Q, Chen Y, Wei D, Wang T, et al. Low REST Expression Indicates a Biomarker of Poor Prognosis in Patients with Renal Cell Carcinoma. BioMed Res Int. 2021;2021. [DOI:10.1155/2021/6682758] [PMID] [PMCID]
  12. Bancroft JD, Gamble M. Theory and practice of histological techniques: Elsevier health sciences; 2008.
  13. Khayal EES, Ibrahim HM, Shalaby AM, Alabiad MA, El‐Sheikh AA. Combined lead and zinc oxide‐nanoparticles induced thyroid toxicity through 8‐OHdG oxidative stress‐mediated inflammation, apoptosis, and Nrf2 activation in rats. Environ Toxicol. 2021;36(12):2589-604. [DOI:10.1002/tox.23373] [PMID]
  14. Shalaby AM, Alabiad MA, El Shaer DF. Resveratrol ameliorates the seminiferous tubules damages induced by finasteride in adult male rats. Microsc. Microanal. 2020;26(6):1176-86. [DOI:10.1017/S1431927620024514] [PMID]
  15. Shalaby AM, Aboregela AM, Alabiad MA, El Shaer DF. Tramadol promotes oxidative stress, fibrosis, apoptosis, ultrastructural and biochemical alterations in the adrenal cortex of adult male rat with possible reversibility after withdrawal. Microsc Microanal. 2020;26(3):509-23. [DOI:10.1017/S1431927620001397] [PMID]
  16. Ahmed MM, Gebriel MG, Morad EA, Saber IM, Elwan A, Salah M, et al. Expression of immune checkpoint regulators, cytotoxic T-lymphocyte antigen-4, and programmed death-ligand 1 in Epstein-Barr virus-associated nasopharyngeal carcinoma. Appl Immunohistochem Mol Morphol. 2021;29(6):401-8. [DOI:10.1097/PAI.0000000000000903] [PMID]
  17. Alabiad MA, Harb OA, Taha HF, El Shafaay BS, Gertallah LM, Salama N. Prognostic and clinic-pathological significances of SCF and COX-2 expression in inflammatory and malignant prostatic lesions. Pathol Oncol Res. 2019;25(2):611-24. [DOI:10.1007/s12253-018-0534-1] [PMID]
  18. Khayal EE-S, Alabiad MA, Elkholy MR, Shalaby AM, Nosery Y, El-Sheikh AA. The immune modulatory role of marjoram extract on imidacloprid induced toxic effects in thymus and spleen of adult rats. Toxicology. 2022;471:153174. [DOI:10.1016/j.tox.2022.153174] [PMID]
  19. Tawfeek SE, Shalaby AM, Alabiad MA, Albackoosh A-AAA, Albakoush KMM, Omira MMA. Metanil yellow promotes oxidative stress, astrogliosis, and apoptosis in the cerebellar cortex of adult male rat with possible protective effect of scutellarin: A histological and immunohistochemical study. Tissue Cell. 2021;73:101624. [DOI:10.1016/j.tice.2021.101624] [PMID]
  20. Elsalam SA, Mansor AE, Sarhan MH, Shalaby AM, Gobran MA, Alabiad MA. Evaluation of apoptosis, proliferation, and adhesion molecule expression in trophoblastic tissue of women with recurrent spontaneous abortion and infected with Toxoplasma gondii. International J Gynecol Pathol. 2021;40(2):124-33. [DOI:10.1097/PGP.0000000000000683] [PMID]
  21. Elshamy AM, Salem OM, Safa MA, Barhoma RA, Eltabaa EF, Shalaby AM, et al. Possible protective effects of CO Q10 against vincristine‐induced peripheral neuropathy: Targeting oxidative stress, inflammation, and sarmoptosis. J Biochem Mol Toxicol. 2022;36(3):e22976. [DOI:10.1002/jbt.22976] [PMID]
  22. Alabiad M, Harb O, Mandour D, Hemeda R, Ahmed RZ, El-Taher A, et al. Prognostic and clinicopathological implications of expression of Beclin-1 and hypoxia-inducible factor 1α in serous ovarian carcinoma: an immunohistochemical study. Pol J Pathol. 2021;72(1):23-38. [DOI:10.5114/pjp.2021.106441] [PMID]
  23. Shalaby AM, Eldin HES, Abdelsameea AA, Abdelnour HM, Alabiad MA, Elkholy MR, et al. Betahistine Attenuates Seizures, Neurodegeneration, Apoptosis, and Gliosis in the Cerebral Cortex and Hippocampus in a Mouse Model of Epilepsy: A Histological, Immunohistochemical, and Biochemical Study. Microsc Microanal. 2022:1-15. [DOI:10.1017/S1431927622012107] [PMID]
  24. Alabiad MA, Elderey MS, Shalaby AM, Nosery Y, Gobran MA. The Usefulness of 4 Immunoperoxidase Stains Applied to Urinary Cytology Samples in the Pathologic Stage of Urothelial Carcinoma: A Study With Histologic Correlation. Appl Immunohistochem Mol Morphol. 2021;29(6):422-32. [DOI:10.1097/PAI.0000000000000905] [PMID]
  25. Zhou L, Ding L, Gong Y, Zhao J, Zhang J, Mao Z, et al. NEK2 promotes cell proliferation and glycolysis by regulating PKM2 abundance via phosphorylation in diffuse large B-cell lymphoma. Front Oncol. 2021:2071. [DOI:10.3389/fonc.2021.677763] [PMID] [PMCID]
  26. Bai R, Yuan C, Sun W, Zhang J, Luo Y, Gao Y, et al. NEK2 plays an active role in tumorigenesis and tumor microenvironment in non-small cell lung cancer. Int J Biol Sci. 2021;17(8):1995. [DOI:10.7150/ijbs.59019] [PMID] [PMCID]
  27. Ahmed MM, Gebriel MG, Morad EA, Saber IM, Elwan A, Salah M, Fakhr AE, Shalaby AM, Alabiad MA. Expression of immune checkpoint regulators, cytotoxic T-lymphocyte antigen-4, and programmed death-ligand 1 in Epstein-Barr virus-associated nasopharyngeal carcinoma. Appl Immunohistochem MolMorphol. 2021;29(6):401-8. [DOI:10.1097/PAI.0000000000000903] [PMID]
  28. Wan J, Xu W, Zhan J, Ma J, Li X, Xie Y, et al. PCAF-mediated acetylation of transcriptional factor HOXB9 suppresses lung adenocarcinoma progression by targeting oncogenic protein JMJD6. Nucleic Acids Res. 2016;44(22):10662-75. [DOI:10.1093/nar/gkw808] [PMID] [PMCID]
  29. Ho Y-J, Shih C-P, Yeh K-T, Shi B, Gong Z, Lin Y-M, et al. Correlation between high expression levels of jumonji domain-containing 4 and short survival in cases of colon adenocarcinoma. Biochem Biophys Res Commun. 2018;503(3):1442-9. [DOI:10.1016/j.bbrc.2018.07.061] [PMID]
  30. Biswas A, Mukherjee G, Kondaiah P, Desai KV. Both EZH2 and JMJD6 regulate cell cycle genes in breast cancer. BMC Cancer. 2020;20(1):1-12. [DOI:10.1186/s12885-020-07531-8] [PMID] [PMCID]
  31. Liu X, Si W, Liu X, He L, Ren J, Yang Z, et al. JMJD6 promotes melanoma carcinogenesis through regulation of the alternative splicing of PAK1, a key MAPK signaling component. Molecular Cancer. 2017;16(1):1-18. [DOI:10.1186/s12943-017-0744-2] [PMID] [PMCID]
  32. Wang F, He L, Huangyang P, Liang J, Si W, Yan R, et al. JMJD6 promotes colon carcinogenesis through negative regulation of p53 by hydroxylation. PLoS Biol. 2014;12(3):e1001819. [DOI:10.1371/journal.pbio.1001819] [PMID] [PMCID]
  33. Liang J, Tong P, Zhao W, Li Y, Zhang L, Xia Y, et al. The REST gene signature predicts drug sensitivity in neuroblastoma cell lines and is significantly associated with neuroblastoma tumor stage. Int J Mol Sci. 2014;15(7):11220-33. [DOI:10.3390/ijms150711220] [PMID] [PMCID]
  34. Zhang P, Lathia JD, Flavahan WA, Rich JN, Mattson MP. Squelching glioblastoma stem cells by targeting REST for proteasomal degradation. Trends Neurosci. 2009;32(11):559-65. [DOI:10.1016/j.tins.2009.07.005] [PMID] [PMCID]
  35. Lawinger P, Venugopal R, Guo Z-S, Immaneni A, Sengupta D, Lu W, et al. The neuronal repressor REST/NRSF is an essential regulator in medulloblastoma cells. Nature Med. 2000;6(7):826-31. [DOI:10.1038/77565] [PMID]
  36. Epping M, Lunardi A, Nachmani D, Castillo-Martin M, Thin T, Cordon-Cardo C, et al. TSPYL2 is an essential component of the REST/NRSF transcriptional complex for TGFβ signaling activation. Cell Death Differ. 2015;22(8):1353-62. [DOI:10.1038/cdd.2014.226] [PMID] [PMCID]
  37. Singh SK, Kagalwala MN, Parker-Thornburg J, Adams H, Majumder S. REST maintains self-renewal and pluripotency of embryonic stem cells. Nature. 2008;453(7192):223-7. [DOI:10.1038/nature06863] [PMID] [PMCID]
  38. Cho E, Moon S-M, Park BR, Kim DK, Lee B-K, Kim CS. NRSF/REST regulates the mTOR signaling pathway in oral cancer cells. Oncol Rep. 2015;33(3):1459-64. [DOI:10.3892/or.2014.3675] [PMID]
  39. Taylor P, Fangusaro J, Rajaram V, Goldman S, Helenowski IB, MacDonald T, et al. REST Is a Novel Prognostic Factor and Therapeutic Target for MedulloblastomaREST Is a Biologic Target in Medulloblastoma. Mol Cancer Ther. 2012;11(8):1713-23. [DOI:10.1158/1535-7163.MCT-11-0990] [PMID] [PMCID]